Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
暂无分享,去创建一个
[1] Tae Min Kim,et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Abernethy,et al. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. , 2014, Journal of oncology practice.
[3] Diane P. Martin,et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. , 2014, Journal of the National Cancer Institute.
[4] T. Choueiri,et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] C. Porta,et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Abernethy,et al. "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. , 2013, Clinical genitourinary cancer.
[7] Lauren McCann,et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.
[8] Robert Hauser,et al. CancerLinQ and the future of cancer care. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[9] K. Scher,et al. Under-representation of older adults in cancer registration trials: known problem, little progress. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] N. Penel,et al. Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: illustration over a 20-year period. , 2012, Contemporary Clinical Trials.
[11] R. Motzer,et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.
[12] Donna M. Zulman,et al. Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials , 2011, Journal of General Internal Medicine.
[13] Jeff Myers,et al. Interconversion of three measures of performance status: an empirical analysis. , 2010, European journal of cancer.
[14] E. Small,et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Kibel. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2009 .
[17] H. Sorbye,et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients , 2009, Cancer.
[18] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Porta,et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.
[20] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[21] M. Gordon,et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .
[22] L. Costa,et al. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. , 2007, The oncologist.
[23] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[24] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[25] Benjamin P. Falit,et al. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. , 2007, Seton Hall law review.
[26] B Nebiyou Bekele,et al. Generalizability of cancer clinical trial results , 2006, Cancer.
[27] Harlan M Krumholz,et al. Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.
[28] M. Fey,et al. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Christian,et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] I. Tannock,et al. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma , 2001, Cancer.